Literature DB >> 31305391

Disappearance of the blood supply to a giant uterine myoma due to childbirth: A CARE-compliant article.

Lu-Jing Li1, Xuan-Kun Liang1, Xian-Xiang Wang1, Dan Zeng2, Zuo-Feng Xu1.   

Abstract

RATIONALE: Giant uterine myomas may be life-threatening due to pressure effects on the lungs and other contiguous organs. PATIENT CONCERNS: A 32-year-old pregnant Asian woman was admitted to our hospital early in her pregnancy with a pre-pregnancy history of multiple uterine myomas. DIAGNOSIS: She was diagnosed with multiple giant uterine myomas in pregnancy.
INTERVENTIONS: No intervention was performed on the woman. OUTCOMES: A reduction in tumor size and disappearance of tumor blood supply were seen on conventional and contrast-enhanced ultrasounds (CEUS) on postpartum day 34. Mass volume gradually decreased and no blood flow signals were seen on CEUS during postpartum follow-up. LESSONS: Childbirth can block the blood supply of giant uterine myomas and reduce mass size. In such cases, childbirth may be considered therapeutic.

Entities:  

Mesh:

Year:  2019        PMID: 31305391      PMCID: PMC6641820          DOI: 10.1097/MD.0000000000016056

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.817


Introduction

Uterine myomas are benign tumors arising from uterine smooth muscle cells and extracellular matrix, occurring in 2.3–10.7% of women in pregnancy.[ The incidence has a tendency of going up recently because of delaying in childbearing. Myomas in pregnant women are usually asymptomatic and found incidentally at clinical or ultrasound examination; however, when symptomatic, they present a variety of symptoms such as abortion, preterm delivery, abruptio placentae, intrauterine growth retardation, dystocia, and postpartum hemorrhage.[ The major complications are mainly related to the location of the myoma, and whether it is in contact with the placenta. Furthermore, women are at increased risk of bleeding and postoperative morbidity because of the increased vascularity of the uterus during pregnancy, especially with a giant uterine myoma. A giant uterine myoma exceeds 11.4 kg in weight.[ Its clinical presentation includes vague abdominal and back pain with abnormal vaginal bleeding. Giant uterine myomas may be life-threatening due to pressure effects on the lungs and other contiguous organs. For these reasons, controversy persists among treatment options of myoma during pregnancy.[ However, there have never been relevant reports about the decreasing of mass volume and of blood flow signals without any interventions after delivery. We mainly put forward a different opinion about the management of myomas for women in pregnancy. We report the rare case of a woman with multiple uterine myomas whose largest tumor, which had gradually grown from 7.5 to 15.3 cm during her pregnancy, lost its blood supply and shrunk after delivery. We describe the color Doppler features of her uterine myomas before and during pregnancy and features on contrast-enhanced ultrasound (CEUS) after delivery.

Patient information

A 32-year-old woman was admitted to our hospital early in her pregnancy (at about 10 gestational weeks) with a pre-pregnancy history of multiple uterine myomas. A conventional ultrasound (US) report from another hospital 6 months pre-pregnancy described several spherical, non-homogeneous, low-echo, intramural uterine tumors with regular morphologies and distinct boundaries, with the largest measuring 7.5 cm × 7.3 cm × 6.9 cm (188.9 mL) in size.

Clinical findings

Physical examination revealed a hard, round, slightly mobile, midline mass palpable in the right lower abdominal quadrant. Liver function, tumor marker, biochemical, and routine blood tests were normal. US examination in our hospital indicated that the largest myoma had grown to 11.5 cm × 10.3 cm × 11.0 cm (651.5 mL), and several circular blood flow signals were found in and around it. A normal, healthy baby was seen in the uterine cavity and two normal ovaries were present as well.

Diagnostic assessment and therapeutic intervention

Four conventional US examinations were performed during the pregnancy. The largest tumor's maximum size was 15.1 cm × 10.3 cm × 12.1 cm (953.4 mL), and rich blood flow signals were detected in and around the tumor (Fig. 1). All related liver function, tumor marker, biochemical, and routine blood tests, and peripheral blood chromosomal examinations were normal. The fetus showed normal development.
Figure 1

Conventional US was shown at 18 + 4 weeks. The maximum size of the tumor was 15.1 cm × 10.3 cm × 12.1 cm (953.4 mL) (A). Color Doppler US shows the circle blood flow signal within and around the uterine myoma (B).

Conventional US was shown at 18 + 4 weeks. The maximum size of the tumor was 15.1 cm × 10.3 cm × 12.1 cm (953.4 mL) (A). Color Doppler US shows the circle blood flow signal within and around the uterine myoma (B). At 37 gestational weeks, a healthy male baby was born by forceps-assisted delivery. Although the whole labor only lasted about 30 minutes, the mother lost more than 800 mL of blood. After delivery, mother and baby were safely transferred to the obstetric ward. Postpartum lochia was prolonged at 74 days, and the patient had slight anemia until it resolved. At 34 days post-parturition, conventional US showed the largest uterine myoma had shrunk to approximately 11.5 cm × 9.2 cm × 11.0 cm (581.9 mL), and there were no blood flow signals within or around the myoma on color Doppler US. CEUSs were successively performed to evaluate the real microcirculation of the largest tumor and showed non-enhancement of the whole tumor on all phases, like after ablation, and no microbubbles (Fig. 2); whereas, the other small myomas all showed homogeneous enhancement and hypervascularity. Blood tests showed slight anemia, with a red blood count of 3.95 × 109/L (4.3 × 109/L–5.8 × 109/L) and a hemoglobin level of 103 g/L (130 g/L–175 g/L).
Figure 2

CEUS on postpartum day 34: the uterine myoma is consecutively non-enhanced.

CEUS on postpartum day 34: the uterine myoma is consecutively non-enhanced.

Follow-up and outcomes

Traditional US and CEUS were repeated at three months, 6 months, and 1 year postpartum. All post-delivery CEUS scans showed non-enhancement, and the largest tumor's volume gradually decreased over time (Fig. 3).
Figure 3

The variation tendency of the volume of the largest tumor was shown.

The variation tendency of the volume of the largest tumor was shown. Informed written consent was obtained from the patient for publication of this case report and accompanying images. Our hospital's Institutional Ethics Committee approved the case report. The authors have no commercial associations that might pose a conflict of interest.

Discussion

Treatment options for uterine myomas in pregnant women include expectant management, medical therapy, surgical treatment, uterine artery embolization, focused ultrasound treatment, and thermal ablation treatment. Although some studies have shown that myomectomy before or during cesarean delivery can be safely performed,[ the cases were in small numbers and there is very little information concerning the efficacy and safety of treatment performed in pregnancy. Furthermore, giant myomas are associated with an increased risk of premature delivery and blood loss at delivery. Therefore, the controversial issue is whether or not to myomectomy should be performed on the giant myomas. There has been an increasing demand for non-hysterectomy options to treat symptomatic uterine myomas. Patients’ reasons for requesting conservative procedures include the desire to maintain childbearing potential, the wish to avoid major surgery, and the belief that the uterus plays a sexual role.[ We described the case of a giant uterine myoma that increased dramatically in volume from 188.9 to 953.6 mL during pregnancy and then gradually shrunk and lost all blood supply following childbirth. This phenomenon has not previously been reported, but may be the result of rapidly reduced postpartum estrogen and progesterone levels. Estrogen and progesterone have been found to affect leiomyoma growth possibly through the regulating growth factors and their signaling pathways.[ In our report, the mean increase in volume during pregnancy is much higher than the mean increase of 12% as reported in the literature.[ The reason may be that the volume of the myoma in our case is so giant that the vascularity of the uterus is abundant during pregnancy. Conventional B-mode US provides information on uterine myoma location, size, and anatomical relations to surrounding organs. Color Doppler US clearly displays the distribution of large vessels within and around uterine myomas. CEUS agents enter the capillary microcirculation and show the perfusion level of target organs with a sensitivity, specificity, and spatial resolution comparable to enhanced CT and MRI studies,[ and can be regarded as giving index assessments of remnant lesions.[ Although CEUS was not performed before or during pregnancy, conventional US showed several large vessels in and around the huge myoma. To better evaluate the tumor microcirculation, CEUS was employed in the postpartum period and, besides the obvious tumor shrinkage, amazingly, the tumor showed complete non-enhancement on all phases. Furthermore, tumor shrinkage and non-vascularity were sustained for more than 1 year after delivery and may persist into the future. In conclusion, childbirth can reduce giant uterine myoma volume and even completely block the blood supply. In that childbirth can be therapeutic for the mother, the baby could be considered the mother's angel.

Author contributions

Conceptualization: Dan Zeng. Data curation: Xuan-Kun Liang, Zuo-Feng Xu. Visualization: Lu-Jing Li, Xian-Xiang Wang, Dan Zeng. Writing – original draft: Lu-Jing Li. Writing – review & editing: Xuan-Kun Liang, Zuo-Feng Xu.
  16 in total

Review 1.  Fibroid in pregnancy: characteristics, complications, and management.

Authors:  Ahmed Zaima; Alok Ash
Journal:  Postgrad Med J       Date:  2011-10-19       Impact factor: 2.401

2.  Giant uterine tumors: case report and review of the literature.

Authors:  H S Jonas; B J Masterson
Journal:  Obstet Gynecol       Date:  1977-07       Impact factor: 7.661

Review 3.  Obstetric complications of fibroids.

Authors:  David W Ouyang; Katherine E Economy; Errol R Norwitz
Journal:  Obstet Gynecol Clin North Am       Date:  2006-03       Impact factor: 2.844

4.  Successful pregnancies with uterine leiomyomas and myomectomy at the time of caesarean section.

Authors:  Yu-Lan Mu; Shan Wang; Jing Hao; Min Shi; Frank D Yelian; Xie-Tong Wang
Journal:  Postgrad Med J       Date:  2011-06-09       Impact factor: 2.401

5.  Outcome of pregnancies in women with uterine leiomyomas identified by sonography in the first trimester.

Authors:  C B Benson; J S Chow; W Chang-Lee; J A Hill; P M Doubilet
Journal:  J Clin Ultrasound       Date:  2001-06       Impact factor: 0.910

6.  Characterization of focal liver lesions: comparison of pulse-inversion harmonic contrast-enhanced sonography with contrast-enhanced CT.

Authors:  Rui Li; Yanli Guo; Xing Hua; Yun He; Jun Ding; Aiming Guo; Mingkui Luo
Journal:  J Clin Ultrasound       Date:  2007 Mar-Apr       Impact factor: 0.910

7.  Pregnancy with fibroids and its and its obstetric complication.

Authors:  Shehla Noor; Ali Fawwad; Ruqqia Sultana; Rubina Bashir; Huma Jalil; Nazia Suleman; Alia Khan
Journal:  J Ayub Med Coll Abbottabad       Date:  2009 Oct-Dec

Review 8.  Receptor tyrosine kinases and their hormonal regulation in uterine leiomyoma.

Authors:  Linda Yu; Alicia B Moore; Darlene Dixon
Journal:  Semin Reprod Med       Date:  2010-04-22       Impact factor: 1.303

9.  Laparoscopic radiofrequency thermal ablation: a new approach to symptomatic uterine myomas.

Authors:  Valentino Bergamini; Fabio Ghezzi; Antonella Cromi; Gaia Bellini; Giovanni Zanconato; Stefano Scarperi; Massimo Franchi
Journal:  Am J Obstet Gynecol       Date:  2005-03       Impact factor: 8.661

10.  Successful myomectomy during pregnancy.

Authors:  D E Lolis; S N Kalantaridou; G Makrydimas; A Sotiriadis; I Navrozoglou; K Zikopoulos; E A Paraskevaidis
Journal:  Hum Reprod       Date:  2003-08       Impact factor: 6.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.